Capstan Therapeutics
USAWho owns Capstan Therapeutics?
Capstan Therapeutics is an American Biotech company, now owned by AbbVie, which acquired it in 2025 from Leaps by Bayer.
Mubadala Capital is still listed as an investor in Capstan Therapeutics, status not confirmed after the 2025 sale.
Hand-verified · updated 2026-04-21
Open JSON · CC-BY
Key facts
Ownership history
2 ownership periods · co-invest detected
Leaps by Bayer sold Capstan Therapeutics to AbbVie in 2025 after 3 years.
More from Leaps by Bayer
Other portfolio companies in the same fund.
More PE-backed in Biotech
Comparable biotech deals from other GPs.
Questions
Who owns Capstan Therapeutics?
Capstan Therapeutics is now owned by AbbVie, which acquired it in 2025 from Leaps by Bayer. Mubadala Capital is still listed as an investor in Capstan Therapeutics, status not confirmed after the 2025 sale.
When did AbbVie acquire Capstan Therapeutics?
AbbVie acquired Capstan Therapeutics in 2025, buying from Leaps by Bayer.
Who did Capstan Therapeutics sell to?
Leaps by Bayer sold Capstan Therapeutics to AbbVie in 2025 (Trade Sale).
Who has owned Capstan Therapeutics over time?
Capstan Therapeutics has been through 2 private-equity ownership periods: Leaps by Bayer · via Leaps by Bayer · 2022–2025 · sold to AbbVie · (Trade Sale); Mubadala Capital · 2022–2025.